Patents by Inventor David Bellovin

David Bellovin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD80 extracellular domain polypeptides and their use in cancer treatment
    Patent number: 10273281
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: April 30, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • B7-H4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190085080
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
    Type: Application
    Filed: August 23, 2018
    Publication date: March 21, 2019
    Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10221244
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: March 5, 2019
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • ANTI-CSF1R ANTIBODY AND ANTI PD-1 ANTIBODY COMBINATION THERAPY FOR CANCER
    Publication number: 20180094067
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: August 18, 2017
    Publication date: April 5, 2018
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • COMBINATION THERAPY FOR CANCER
    Publication number: 20180085472
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
    Type: Application
    Filed: April 12, 2016
    Publication date: March 29, 2018
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Emma Masteller, Thomas Brennan, David Bellovin, Kevin Baker, Brian Wong
  • SLAMF1 ANTAGONISTS AND USES THEREOF
    Publication number: 20180016555
    Abstract: Methods of identifying and using SLAMF1 antagonists are provided.
    Type: Application
    Filed: October 21, 2015
    Publication date: January 18, 2018
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Luis Borges, Nathan Sallee, Charles Kaplan, Arthur Brace, W. Michael Kavanaugh, Brian Wong, David Bellovin, Thomas Brennan, Artur Karasyov
  • Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
    Patent number: 9775881
    Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 3, 2017
    Assignees: Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: David Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
  • Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 9765147
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: September 19, 2017
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT
    Publication number: 20170145071
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Application
    Filed: November 1, 2016
    Publication date: May 25, 2017
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • COMBINATION THERAPY FOR CANCER
    Publication number: 20160152715
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: October 28, 2015
    Publication date: June 2, 2016
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • METHODS OF TREATING CANCER
    Publication number: 20160106809
    Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 21, 2016
    Inventors: David Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar